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Abstract
Background: Studies of survival comparing radical cystectomy (RC) and radiother-
apy for muscle‐invasive bladder cancer have provided inconsistent results and have 
methodological limitations. The aim of the study was to investigate risk of death after 
radiotherapy as compared to RC.
Methods: We selected patients with muscle‐invasive urothelial carcinoma without 
distant metastases, treated with radiotherapy or RC from 1997 to 2014 in the Bladder 
Cancer Data Base Sweden (BladderBaSe) and estimated absolute and relative risk of 
bladder cancer death and all‐cause death. In a group of patients, theoretically eligible 
for a trial comparing radiotherapy and RC, we calculated risk difference in an instru-
mental variable analysis. We have not investigated chemoradiotherapy as this treat-
ment was not used in the study time period.
Results: The study included 3 309 patients, of those 17% were treated with radio-
therapy and 83% with RC. Patients treated with radiotherapy were older, had more 
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1 |  INTRODUCTION
Surgical removal of the urinary bladder, radical cystec-
tomy (RC), is the recommended treatment for muscle‐in-
vasive bladder cancer in most parts of the world, including 
Sweden,1 but with international variations.2 RC entails high 
risk of re‐operations, long hospital‐stays, long‐term se-
quelae, and even postoperative mortality.3,4 A contemporary 
bladder‐sparing treatment alternative to RC is chemoradio-
therapy.5-8 There is no evidence from randomized controlled 
trials to support superiority of RC over radiotherapy with 
respect to survival. The largest trial to date was closed due 
to poor accrual,9 and a recent review concluded that obser-
vational studies comparing outcomes of RC to bladder‐spar-
ing therapies had serious methodological shortcomings and 
inconsistent findings.10
The aim of this population‐based observational cohort 
study was to investigate the risk of bladder‐cancer specific 
and all‐cause death using detailed individual data on patient 
demographics, tumor characteristics, provided treatment, 
comorbidity, and follow‐up in patients with muscle‐inva-
sive urothelial carcinoma, clinically free of metastases, and 
treated with radiotherapy or RC.
2 |  MATERIALS AND METHODS
2.1 | The bladder cancer data base Sweden 
(BladderBaSe)
The study is based on patients diagnosed with primary mus-
cle‐invasive disease in the Bladder Cancer Data Base Sweden 
(BladderBaSe). The BladderBaSe was initiated in 2015 
via linkage of the Swedish National Register for Urinary 
Bladder Cancer (SNRUBC) to a number of health care and 
demographic registers.11 The project was approved by the 
Research Ethics Board at Uppsala University, Sweden.
We retrieved data on diagnosis and treatment for patients 
reported to the SNRUBC from 1 January 1997 to 31 December 
2014. Data included date of diagnosis, diagnosing unit, mor-
phological code, grade (G1, G2, G3, and GX), clinical T cat-
egory (T0, Tis, Ta, T1, T2, T3, T4, and TX), N category (N0, 
N1, N2, N3, and NX), and M category (M0, M1, and MX) at 
diagnosis. Morphological codes were classified according to 
World Health Organization's International Classification of 
Diseases for Oncology, 3rd edition (ICD‐O/3). Clinical clas-
sification of N category was based on computed tomography 
and/or magnetic resonance imaging examinations of the ab-
domen, and N0 was defined as no evidence of regional lymph 
node metastases. Classification of M category was based on 
clinical findings and computed tomography or x‐ray exam-
inations of the chest; and M0 was defined as no evidence of 
distant metastases. During 3 years in the SNRUBC, clinically 
node‐positive patients were only categorized as node‐positive 
without any further N classification. This group (less than 
3% of patients with muscle‐invasive bladder cancer) was in 
the analysis categorized as N1 if they had grade 1, 2, or T 
category T2, and as N3 if they were M1, and the remain-
ing node‐positive patients were categorized as N2. In 2013, 
the SNRUBC adapted the criteria for N1‐N3 to the 2009 
TNM‐system.
Treatment data included reporting unit and primary treat-
ment (RC, radiotherapy, intravesical treatment, or systemic 
chemotherapy), and further primary treatment registered 
within 6 months from date of diagnosis. The reporting unit 
was categorized into university, county, or district hospi-
tals. During the investigated time period, the primary treat-
ment with curative intent for muscle‐invasive bladder cancer 
was RC, with neoadjuvant chemotherapy prior to RC being 
advanced comorbidity, and had a higher risk of death as compared to patients treated 
with RC (relative risks of 1.5‐1.6). In the “trial population,” all‐cause death risk dif-
ference was 6 per 100 patients lower after radiotherapy at 5 years of follow‐up, 95% 
confidence interval −41 to 29.
Conclusion(s): Patient selection between the treatments make it difficult to evaluate 
results from conventionally adjusted and propensity‐score matched survival analysis. 
When taking into account unmeasured confounding by instrumental variable analy-
sis, no differences in survival was found between the treatments for a selected group 
of patients. Further clinical studies are needed to characterize this group of patients, 
which can serve as a basis for future comparison studies for treatment 
recommendations.
K E Y W O R D S
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gradually introduced. Patients with contraindications for RC 
or unwilling to accept RC were treated with radiotherapy.1 
Radiotherapy treatment included whole pelvic radiation up 
to 70 Gray, with regional variations of hyper fractionated ra-
diation during the earlier time period. We had no intention to 
investigate chemoradiotherapy as this treatment was not used 
in the study time period.
We used data from the National Patient Register on dis-
charge diagnoses from hospital admissions up to 10 years 
prior to the date of bladder cancer diagnosis to calculate 
the Charlson Comorbidity Index (CCI), which was cate-
gorized into four groups: no comorbidity, 1, 2, and ≥ 3 
comorbidities. Data on educational level were retrieved 
from the Longitudinal Integration Database for Health 
Insurance and Labor Market Studies at Statistics Sweden 
and categorized into three groups: ≤9 years, 10‐12 years, 
and ≥ 13 years of education, corresponding to low, inter-
mediate, and high education level. To detect salvage cys-
tectomies after radiotherapy, we retrieved data of bladder 
cancer (International Classification of Diseases, 10th revi-
sion [ICD‐10] code C67) and RC (procedure code KCC) or 
complete pelvic evisceration (procedure code LCE) from 
the National Patient Register. Date and cause of death were 
obtained from the Cause of Death Register and death from 
bladder cancer was defined as ICD‐10 code C67 as under-
lying death cause.
2.2 | Selection of study population
Patients with primary muscle‐invasive urothelial carcinoma 
in the bladder without metastases (clinical T category ≥ 2, 
N0 and M0), treated with RC or radiotherapy were selected 
for the current study. Prior to selection of the study popula-
tion, and in order to account for possible differences in the 
diagnostic workup between the groups, we imputed data on 
grade, N and M category for patients with clinical T cate-
gory ≥ 2 and stage missing or categorized as X for grade, 
N or M category. The multiple imputations were based on 
predicted mean matching with five imputed datasets.12 Data 
on gender, age at diagnosis, date of diagnosis, health‐care re-
gion, educational level, marital status, CCI, size of reporting 
unit, clinical T category at diagnosis, follow‐up time, deci-
sion of further primary treatment, RC, radiotherapy, intraves-
ical treatment, systemic chemotherapy, bladder cancer death, 
and other cause of death were used as independent variables 
for the imputation.
To provide an analysis that mimics results from a ran-
domized controlled trial,13 we created a group of patients 
comparable to those eligible for a recent trial comparing ra-
diotherapy and RC.14 For this “trial population,” we selected 
patients who were 60‐80 years of age at diagnosis, had clin-
ical T category 2 or 3, and CCI less than 3 from the study 
population described above.
2.3 | Statistical analysis
Starting date of the study was the date of diagnosis, and 
last date of the study was date of death, emigration, or 31 
December 2014, whichever happened first. Time in years 
from diagnosis was used as timescale in all analyses.
Absolute risk of bladder cancer death and other causes 
of death were calculated by cumulative incidence functions 
using competing risk analysis.15 In these models, bladder can-
cer death was used as the main endpoint and other causes of 
death as a competing endpoint. Relative risk (hazard ratios) 
of bladder cancer death and all‐cause death were assessed by 
Cox proportional hazard models using RC as reference cat-
egory, and adjusted for age at diagnosis (continuous), calen-
dar year at diagnosis (1997‐2005 and 2006‐2014), education 
level, gender, marital status, comorbidity, health‐care region, 
reporting unit, grade, systemic chemotherapy, and T cate-
gory. The assumption of proportional hazard was tested by 
adding an interaction term for treatment with time in a sepa-
rate Cox model.16 If deviations from the proportional hazards 
assumption were found, hazard ratios at specific points in 
time were calculated.
In the “trial population,” we calculated propensity‐score 
matched relative risks and risk differences using instru-
mental variable analysis, details, and assumptions of these 
methods are described in Methods S1. We used treatment 
preference in the treating units to define the instrument, 
which was quantified by the proportion (0‐1) of RCs among 
previous patients at the same unit, whilst excluding the first 
patient in each unit from the analysis. All analyses were 
performed with STATA MP/2 version 14 (StataCorp LP, 
College Station, Texas).
3 |  RESULTS
From the 8 954 patients with primary muscle‐invasive 
urothelial carcinoma in BladderBaSe, we identified 3 309 
patients with no metastases whom were treated with either 
radiotherapy or RC (as presented in Figure 1). Mean age 
at the start of study was 70 (SD = 9, median = 71, range 
(36, 92)), and 17% of the patients were treated with ra-
diotherapy and 83% with RC (Table 1). Baseline data 
indicated that the two treatment groups had a similar dis-
tribution with respect to gender, clinical T category, and 
grade, but large differences in age at diagnosis and comor-
bidity. Systemic chemotherapy was given to 4% of patients 
treated with radiotherapy and 19% of patients treated with 
RC, and salvage cystectomy was recorded for 3% of pa-
tients treated with radiotherapy. During a mean follow‐up 
time of 4 years (SD = 4, median = 2, range (0, 18)), 39% 
of the study participants died of bladder cancer and 19% 
died of other causes.
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Patients treated with radiotherapy, as compared to RC, 
had a higher risk of bladder cancer death and all‐cause death. 
Five years after diagnosis, the absolute risk of bladder cancer 
death was 51% (95% CI, 47%‐55%) for patients treated with 
radiotherapy, and 39% (95% CI, 37%‐41%) for RC (Figure 
2). Corresponding risks for all‐cause death were 77% (95% 
CI, 69%‐85%) and 51% (95% CI, 47%‐54%), respectively. 
Relative risks of bladder cancer death and all‐cause death 
for radiotherapy versus RC increased with time from diag-
nosis. At 2 years from diagnosis, the multivariable adjusted 
relative risk was 1.58 for bladder cancer death and 1.54 for 
all‐cause death. At 5 years from diagnosis, the corresponding 
risks were 2.38 and 2.19, respectively (Table 2), derived from 
results in Table S1.
The “trial population” included 2 154 patients from the 
study population matching the SPARE‐trial inclusion criteria10 
as described above and in Figure 1. In this “trial population,” 
13% were treated with radiotherapy and 87% with RC, with 
similar results as the entire study population, Table 2, Table 
S2, Table S4, and Figure S1. After exclusion of the first patient 
in each reporting unit, we performed an instrumental variable 
analysis of the 2 104 patients in the “trial population.” An anal-
ysis of the assumptions for the instrumental variable analysis is 
shown in Tables S3 and Table S5, and Figure S2. Results from 
the two‐stage least squares regression of the instrument showed 
an adjusted risk difference at 5 years after diagnosis—2 (95% 
CI, −48 to 43) events of bladder cancer death and −6 (95% 
CI, −41 to 29) events of all‐cause deaths, implying only a 
small difference between the treatment groups Table 3. These 
point estimates show a decreased risk for radiotherapy as com-
pared to RC of 2 events of bladder cancer death and 6 events 
of all‐cause death, per 100 patients, but with large confidence 
intervals. For comparison, we have also calculated these risk 
differences using ordinary least squares regression (Table S6).
4 |  DISCUSSION
Patients with muscle‐invasive urothelial carcinoma without 
metastases treated with radiotherapy as compared with RC 
had higher risk of bladder cancer death and all‐cause death. 
However, when taking patient selection into account and re-
stricting the population to those eligible for a trial, our data 
implied similar survival for a group of patients with high 
likelihood of both treatments.
The main strengths of the current study are the sample 
size, the quality of the data, and the nation‐wide recruitment 
base. We had access to several high‐quality, nationwide reg-
isters with detailed data on tumor characteristics, treatment, 
and covariates such as comorbidity and education level.11 
We used multiple imputations to account for selection mech-
anisms to either treatment, in combination with instrumental 
variable analysis to account for patient selection between the 
treatment groups, not detected by the covariates.17 The main 
limitations are the difference in characteristics between the 
treatment groups as a result of the national treatment guide-
lines, and an uncertainty in the received radiotherapy dose. 
Moreover, we have no information about received dose and 
treatment fields for the patients treated with radiotherapy. 
As we have no data of patients not receiving the full dose 
of external beam radiation, we have performed the study on 
an intention‐to‐treat basis, thus, we have not accounted for 
incomplete treatments. Data in the SNRUBC have not been 
systematically validated versus clinical journals; hence, we 
have no information of the proportion of misclassification 
in the separate variables. Moreover, regional lymph nodes 
were not irradiated, and pelvic lymphadenectomy was an 
integral part of most patients treated with RC (only 11% 
of the study population treated after 2008 did not undergo 
a lymphadenectomy). In the SNRUBC, treatment with ra-
diotherapy was classified as curative from 2008 onwards. 
Before 2008, radiotherapy could also be registered as non‐
curative; however, as the guidelines do not support pallia-
tive radiotherapy for this study population, we believe the 
number of individuals treated with palliative radiation is 
negligible. We tried to overcome this misclassification of 
F I G U R E  1  Flowchart that describes the selection of patients for 
the study from the Bladder Cancer Data Base Sweden (BladderBaSe), 
1997 to 2014. *Pooled estimate of five imputations
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the exposure by selecting patients with urothelial carcinoma 
with no metastases, and to perform an analysis restricted to 
patients that theoretically could be included in a randomized 
controlled trial. However, we have not been able to assess all 
inclusion criteria, such as hydronephrosis and the presence 
of widespread carcinoma in situ.14,18
T A B L E  1  Baseline characteristics of the entire study population with respect to actual treatment
Covariate Categories
Radical Cystectomy Radiotherapy
N = 2 733* N = 576* 
Gender Men 75% 76%
Women 25% 24%
Age Below 75 years 75% 31%
75 years and above 25% 69%
Calendar year of diagnosis 1997‐2005 42% 50%
2006‐2014 58% 50%
Clinical T category T2 77% 75%
T3 18% 18%
T4 6% 6%
Grade** G2 12% 12%
G3 88% 88%




Education level *** Low 45% 55%
Medium 37% 33%
High 18% 12%
Marital status Married 60% 54%
Divorced/Widowed 28% 38%
Unmarried 12% 8%






Reporting unit category University hospitals 45% 36%
County hospitals 41% 43%
District hospitals 14% 20%
Systemic chemotherapy Yes 19% 4%
No/NA 81% 96%
Neoadjuvant chemotherapy**** Yes 13% 2%
No/NA 87% 98%
Adjuvant chemotherapy**** Yes 5% 1%
No/NA 95% 99%
CCI, Charlson Comorbidity Index.
*Pooled estimate of five imputations. The entire study population varied between 3298 and 3318 patients.
**Participants with value G1 were added to G2 (<1% of data prior to multiple imputation). From 2004, the WHO 1999‐grading system was used, previously, the WHO 
1973‐grading was used.
***Participants with missing education level were added to low (5% of data prior to multiple imputation).
****Participants with year of diagnosis 1999 or later included.
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This study aimed to address survival after radiotherapy 
vs RC over a period of more than 15 years. During this time, 
the guidelines for both RC and radiotherapy have changed. 
The Swedish guidelines from May 2013 have recommended 
chemoradiotherapy over radiotherapy alone; however, 
during the study period chemoradiotherapy was not applied. 
However, these changes in guidelines have in most studies 
improved the survival marginally for both treatments. As 
these changes have not been implemented in a consistent 
manner, the current study has not been able to specifically ac-
count for those differences over the study period. We had no 
intention to investigate chemoradiotherapy,8,19-23 which has 
been reported to provide improved survival in comparison to 
radiotherapy, because this combined treatment‐modality was 
not used in Sweden during the study period. Furthermore, 
some patients might be unsuitable for concurrent chemother-
apy due to specific comorbidities, and were subsequently 
treated with radiotherapy as the second best bladder‐sparing 
option. Moreover, we did not categorize patients differently 
depending on perioperative chemotherapy given in associa-
tion with RC, as the majority of patients treated with RC did 
not receive any of these treatments, and we had no intention 
F I G U R E  2  Absolute risk of death, 
separated by bladder cancer death and all‐
cause of death for patients with metastasis‐
free muscle‐invasive urothelial carcinoma 
treated with radical cystectomy (RC) and 
radiotherapy in the entire study population
T A B L E  2  Estimates of relative risk (hazard ratios) of treatment (radiotherapy versus RC) for bladder cancer death and all‐cause death in the 
entire study population and “trial population” using multivariate adjusted and propensity‐score matched analysis at different point in times from 













Bladder cancer death, HR (95% CI)
RC — 1, ref 1, ref 1, ref
Radiotherapy 2 years 1.58 (1.12‐2.22) 1.67 (1.06‐2.64) 1.53 (0.85‐2.77)
 5 years 2.38 (1.36‐4.15) 2.40 (1.15‐4.98) 2.37 (0.90‐6.24)
 Any year 1.52 (1.31‐1.77)* 1.64 (1.33‐2.00)* 1.51 (1.17‐1.94)* 
All‐cause death, HR (95% CI)
RC — 1, ref 1, ref 1, ref
Radiotherapy 2 years 1.54 (1.20‐1.97) 1.61 (1.16‐2.22) 1.39 (0.93‐2.07)
 5 years 2.19 (1.51‐3.18) 2.12 (1.30‐3.45) 1.73 (0.96‐3.13)
 Any year 1.62 (1.43‐1.83)* 1.70 (1.44‐2.01)* 1.49 (1.23‐1.81)* 
Multivariate models were adjusted for age at diagnosis (continuous), calendar year at diagnosis (in two categories), education level, gender, marital status, comorbidity, 
health‐care region, reporting unit category, T category, systemic chemotherapy, and grade.
RC, radical cystectomy.
*Proportional hazards assumption violated.
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to investigate subgroups where RC or radiotherapy would be 
more beneficial. The absence of information about clinically 
prognostic factors such as extent of transurethral resection 
prior to radiotherapy, performance status, and information 
on presence of hydronephrosis prior to treatment were not 
available. Thus, adjustment for these factors was not possible 
in the present study.
The optimal design for the current research question is a 
prospective randomized controlled trial. However, the larg-
est trial to date investigating radiotherapy vs RC in terms of 
overall survival requiring a sample size of 1 015 patients was 
closed prematurely due to poor accrual.9,14,18 Another trial 
from the 1980s based on 189 patients, found no statistically 
significant difference in overall survival, but indicated that 
the prognosis was influenced by age, gender, treatment re-
sponses, and tumor characteristics.22 In the absence of ran-
domized results, real‐world results from population‐based 
observational studies can provide useful complementary data 
with high validity,14,23 despite the restrictions mentioned 
above.
Similar to most previous observational reports, baseline 
data in our study showed substantial differences in age and co-
morbidity between the treatments.24,25 Previous studies show 
5‐year overall survival for radiotherapy ranging from 21% to 
30% and for RC from 36% to 47%,24,25 and most relative risk 
estimates of all‐cause death using standard multivariable ad-
justments are in the range of 1.4‐1.5,25,26 with an exception 
of a recent study with an estimate of 2.27 The relative risk 
estimates in our study increased with time from diagnosis. 
Previous studies have reported evidence of nonproportional 
hazards over time. For example, a very recent comparison of 
RC to chemoradiotherapy reported a relative risk decrease 
over time using chemoradiotherapy as reference group,28 and 
has in another study not been investigated further.26
We accounted for patient selection between the treat-
ments by use of an instrumental variable analysis. When 
applying this method, the results showed similar survival 
between the treatments, but with a wide confidence inter-
val. Given that the instrumental variable assumptions are 
valid, the analysis is expected to provide an estimate closer 
to the true treatment effect than relative risk estimates.29,30 
We have used the recommended guidelines for reporting 
instrumental variable analysis;31 however, as some of the 
underlying assumptions cannot be empirically verified,17 
there is always a possibility that our analysis might violate 
some of these assumptions.32
A large Canadian cohort study of 5 259 patients reported 
no differences in cancer‐specific survival for patients treated 
with radiotherapy as compared to RC after propensity score 
matching, and patients treated with radiotherapy had slightly 
higher overall survival after 5 years.24 Other large studies 
using instrumental variable analysis have reported inconsis-
tent results: both no survival differences26 and better survival 
for patients treated with RC.25
Much like other international settings, the Swedish national 
guidelines recommends radiotherapy to patients with high‐sur-
gical risk. This treatment selection may have therefore ham-
pered the possibility to accurately evaluate radiotherapy as an 
alternative to RC in a retrospective manner. The unadjusted 
absolute risk estimates and the relative risk estimates can be 
generalized to populations of patients with similar background 
characteristics, treatment and progression patterns as the cur-
rent study. In contrast, estimates from the instrumental variable 
analysis reflect results in those patients in whom the treatment 
choice depends on the instrument, that is, to the patients who 
would have been treated differently depending on treatment 
preferences in the units.26,33 We speculate that this group of pa-
tients are more often older and/or frail, as compared to those 
that would be offered RC regardless of treating unit.
In conclusion, patient selection mechanisms make it dif-
ficult to evaluate results from conventionally adjusted or pro-
pensity‐score matched survival analysis comparing RC and 
radiotherapy. When taking into account unmeasured con-
founding by instrumental variable analysis, similar survival 
for the treatments were found for a group of patients which 
we speculate to include a selection of older and/or frail pa-
tients in the “trial population.” Further observational studies 
are needed to characterize this group with similar survival 
regardless of treatment, which can serve as a basis for future 
comparisons with respect to modern chemoradiotherapy.
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